J
Junjie Peng
Researcher at Fudan University
Publications - 96
Citations - 1855
Junjie Peng is an academic researcher from Fudan University. The author has contributed to research in topics: Medicine & Colorectal cancer. The author has an hindex of 20, co-authored 66 publications receiving 1172 citations. Previous affiliations of Junjie Peng include Fudan University Shanghai Medical College.
Papers
More filters
Journal ArticleDOI
Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer
Ye Yao,Xiaoya Xu,Lifeng Yang,Ji Zhu,Juefeng Wan,Lijun Shen,F. Xia,Guoxiang Fu,Yun Deng,Mengxue Pan,Qiang Guo,Xiaoxue Gao,Yuanchuang Li,Xinxin Rao,Yi Zhou,Liping Liang,Yaqi Wang,Jing Zhang,Hui Zhang,Guichao Li,Lixing Zhang,Junjie Peng,Sanjun Cai,Chen Hu,Jianjun Gao,Hans Clevers,Zhen Zhang,Guoqiang Hua +27 more
TL;DR: A living organoid biobank is generated from patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation (NACR) enrolled in a phase III clinical trial to imply that PDOs predict LARC patient responses in the clinic and may represent a companion diagnostic tool inrectal cancer treatment.
Journal ArticleDOI
Epithelial EZH2 serves as an epigenetic determinant in experimental colitis by inhibiting TNFα-mediated inflammation and apoptosis
Yongfeng Liu,Junjie Peng,Tongyu Sun,Ni Li,Le Zhang,Jiale Ren,Huairui Yuan,Shan Kan,Qiang Pan,Xiang Li,Yufeng Ding,Min Jiang,Xiaoji Cong,Minjia Tan,Yushui Ma,Da Fu,Sanjun Cai,Yichuan Xiao,Xiaoming Wang,Jun Qin +19 more
TL;DR: EZH2 depletion compromises the protective role of NF-κB signaling in cell survival by directly up-regulating ITCH, a well-known E3 ligase that degrades the c-FLIP protein, and indicates that EZH 2 serves as an epigenetic brake to modulate TNFα functions in colitis.
Journal ArticleDOI
Perineural invasion in pT3N0 rectal cancer: the incidence and its prognostic effect.
TL;DR: The authors' purpose was to explore the incidence and prognostic significance of perineural invasion (PNI) in pT3N0 rectal cancer.
Journal ArticleDOI
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety
Huiyan Luo,Y. Li,W. H. Wang,Z. Wang,Xianglin Yuan,Dong Ma,Fulong Wang,Dingmei Zhang,D. R. Lin,Y. C. Lin,J. Jia,X. H. Hu,Junjie Peng,R. Xu +13 more
TL;DR: Maintenance therapy with a single agent of capecitabine can be considered an appropriate option following the induction of XELOX or FOLFOX in mCRC patients with acceptable toxicities.
Journal ArticleDOI
Prognostic Significance of the Metastatic Lymph Node Ratio in Node-Positive Rectal Cancer
TL;DR: Multivariate analysis revealed that LNR as a continuous variable was the most significant prognostic factor for DFS, OS, and LR and is an important prognostic factors for node-positive rectal cancers.